Journal of Leukocyte Biology eBioscience full spectrum cell analysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burke, B.
Right arrow Articles by Lewis, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burke, B.
Right arrow Articles by Lewis, C. E.
(Journal of Leukocyte Biology. 2002;72:417-428.)
© 2002 by Society for Leukocyte Biology

Macrophages in gene therapy: cellular delivery vehicles and in vivo targets

B. Burke*, S. Sumner{dagger}, N. Maitland{ddagger} and C. E. Lewis{dagger}

* Department of Microbiology and Immunology, University of Leicester, United Kingdom;
{dagger} Tumor Targeting Group, Section of Oncology & Cellular Pathology, Division of Genomic Medicine, University of Sheffield Medical School, United Kingdom; and
{ddagger} YCR Cancer Research Unit, Department of Biology, University of York, United Kingdom

Correspondence: Dr. B. Burke, Department of Microbiology and Immunology, Maurice Shock Building, University of Leicester, University Road, Leicester LE1 9HN, UK. E-mail: bb14{at}leicester.ac.uk

The appearance and activation of macrophages are thought to be rapid events in the development of many pathological lesions, including malignant tumors, atherosclerotic plaques, and arthritic joints. This has prompted recent attempts to use macrophages as novel cellular vehicles for gene therapy, in which macrophages are genetically modified ex vivo and then reintroduced into the body with the hope that a proportion will then home to the diseased site. Here, we critically review the efficacy of various gene transfer methods (viral, bacterial, protozoan, and various chemical and physical methods) in transfecting macrophages in vitro, and the results obtained when transfected macrophages are used as gene delivery vehicles. Finally, we discuss the use of various viral and nonviral methods to transfer genes to macrophages in vivo. As will be seen, definitive evidence for the use of macrophages as gene transfer vehicles has yet to be provided and awaits detailed trafficking studies in vivo. Moreover, although methods for transfecting macrophages have improved considerably in efficiency in recent years, targeting of gene transfer specifically to macrophages in vivo remains a problem. However, possible solutions to this include placing transgenes under the control of macrophage-specific promoters to limit expression to macrophages or stably transfecting CD34+ precursors of monocytes/macrophages and then differentiating these cells into monocytes/macrophages ex vivo. The latter approach could conceivably lead to the bone marrow precursor cells of patients with inherited genetic disorders being permanently fortified or even replaced with genetically modified cells.

Key Words: vector • adoptive immunotherapy • transfection • homing • transcriptional targeting




This article has been cited by other articles:


Home page
 CVIHome page
B. E. Potts, M. L. Hart, L. L. Snyder, D. Boyle, D. A. Mosier, and S. K. Chapes
Differentiation of C2D Macrophage Cells after Adoptive Transfer
Clin. Vaccine Immunol., February 1, 2008; 15(2): 243 - 252.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
M. Stec, K. Weglarczyk, J. Baran, E. Zuba, B. Mytar, J. Pryjma, and M. Zembala
Expansion and differentiation of CD14+CD16 and CD14++CD16+ human monocyte subsets from cord blood CD34+ hematopoietic progenitors
J. Leukoc. Biol., September 1, 2007; 82(3): 594 - 602.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. E. M. Dirkx, M. G. A. oude Egbrink, J. Wagstaff, and A. W. Griffioen
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis
J. Leukoc. Biol., December 1, 2006; 80(6): 1183 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Ikehara, T. Niwa, L. Biao, S. K. Ikehara, N. Ohashi, T. Kobayashi, Y. Shimizu, N. Kojima, and H. Nakanishi
A Carbohydrate Recognition-Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle.
Cancer Res., September 1, 2006; 66(17): 8740 - 8748.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Lewis and C. Murdoch
Macrophage Responses to Hypoxia: Implications for Tumor Progression and Anti-Cancer Therapies
Am. J. Pathol., September 1, 2005; 167(3): 627 - 635.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. S. Lee, Z. Hmama, A. Mui, and N. E. Reiner
Stable Gene Silencing in Human Monocytic Cell Lines Using Lentiviral-delivered Small Interference RNA: SILENCING OF THE p110{alpha} ISOFORM OF PHOSPHOINOSITIDE 3-KINASE REVEALS DIFFERENTIAL REGULATION OF ADHERENCE INDUCED BY 1{alpha},25-DIHYDROXYCHOLECALCIFEROL AND BACTERIAL LIPOPOLYSACCHARIDE
J. Biol. Chem., March 5, 2004; 279(10): 9379 - 9388.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
R. Raouf, Y. Chakfe, D. Blais, A. Speelman, E. Boue-Grabot, D. Henderson, and P. Seguela
Selective Knock-Down of P2X7 ATP Receptor Function by Dominant-Negative Subunits
Mol. Pharmacol., March 1, 2004; 65(3): 646 - 654.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Leukocyte Biology.